Useless, describes a stroke risk factor but provides NO PROTOCOL on how to reduce that risk.
Serum β2-Microglobulin Is Closely Associated With the Recurrence Risk and 3-Month Outcome of Acute Ischemic Stroke
- 1Stroke Center & Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
- 2School of Public Health, Bengbu Medical College, Bengbu, China
- 3Department of Neurology, The No. 2 People's Hospital of Hefei, Hefei, China
- 4Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Background and Purpose: Inflammation
plays a significant role in the pathogenesis of acute ischemic stroke
(AIS). The role of β2-microglobulin (β2M) as a potential initiator of
the inflammatory response in AIS is unclear. The purpose of this study
was to analyze the relationship of serum β2M with the recurrence risk
and 3-month outcome of AIS.
Methods: A total of 205 patients with
AIS were recruited, and their clinical and biochemical characteristics
were collected. All patients were followed up for 3 months after stroke
onset, and the occurrence of death or major disability at 3 months after
onset was the outcome of interest in this study. We evaluated the
association of serum β2M levels with the National Institute of Health
Stroke Scale (NIHSS) scores, modified Rankin Scale (mRS) scores, and
Essen Stroke Risk Score (ESRS) values in patients with AIS. Then, we
used receiver operating curve analysis to calculate the optimal cutoff
value for discriminating outcomes in patients with AIS and a binary
logistic regression model to evaluate the risk factors for a poor
outcome after AIS.
Results: Our results showed that serum β2M levels were significantly and positively correlated with ESRS values (r = 0.176, P < 0.001) and mRS scores (r = 0.402, P < 0.001), but the levels of β2M were not correlated with NIHSS scores (r = 0.080, P = 0.255) or with infarct volume (r = 0.013, P
= 0.859). In a further study, we found that 121 patients (59.02%) had
poor outcomes. The optimal β2M cutoff to predict the 3-month outcome of
AIS in this study was 1.865 mg/l, and β2M was independently associated
with a poor outcome at 3 months (OR = 3.325, 95% confidence interval: 1.089~10.148).
Conclusions: In conclusion, we inferred
that serum β2M was positively associated with the recurrence risk and
3-month outcome of AIS, but it did not appear to be directly related to
the severity of AIS or the size of the infarct at admission.
No comments:
Post a Comment